No let-up in Spain for pharma as austerity measures keep on coming
This article was originally published in SRA
There have already been price cuts for branded drugs and pro-generic prescribing measures. Even more radical change is in store as the Spanish government prepares the way for introducing, among other things, value-based pricing for new drugs, reports Esther Minguell.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.